PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies

2024-05-03
(Press-News.org) Activated T cells that carry a certain marker protein on their surface are controlled by natural killer (NK) cells, another cell type of the immune system. In this way, the body presumably curbs destructive immune reactions. Researchers from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM) now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors (ICI) in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells. Interventions in this mechanism could potentially improve the efficacy of these cellular cancer immunotherapies.

The T cells of the immune system are the main players in the defense against viral infections and tumor cells. On the other hand, they attack the body's own healthy tissue in autoimmune reactions, which can even be fatal. The body must therefore keep a tight control on T cell activity.

A large number of molecules and messenger are involved in the highly complex regulation of T cell activity. Only recently have researchers discovered that another group of immune cells contibutes to the control of T cell activity. Natural killer cells (NK cells) are part of the innate immunity, i.e. the rapid response force that quickly detects and eliminates infected or malignant cells.

"Studies have shown that NK cells can also kill activated T cells and thus limit their proliferation," says Michael Platten, Head of Department at the DKFZ and Director of the Neurological University Clinic Mannheim. "However, until now we did not know which feature characterizes T cells as a target for the NK cell."

When screening activated T cells from healthy donors, Platten's team identified the protein B7H6 as a recognition molecule for NK cell attacks in a new study. Activated T cells from the blood of patients with autoimmune diseases, cancer or viral infections expose large amounts of B7H6 on their surface. Co-culture experiments in the culture dish showed that NK cells recognize the activated T cells by their B7H6 expression. In contrast, T cells whose B7H6 gene was destroyed with the CRISPR-Cas were protected from the lethal attack of the NK cells.

"The elimination of T cells by NK cells is triggered by an intrinsic mechanism of the T cells. The activated T cells temporarily identify themselves as targets for NK-induced cell lysis," explains Michael Kilian, first author of the publication, and adds: "This may limit excessive activation and expansion of T cells as a control mechanism to curb destructive immune responses."

Immune checkpoint inhibitor therapies are neutralized by NK cells

"We now know a number of so-called checkpoint molecules that reduce or enhance the activation of T cells and thus modulate the course of immune reactions. B7H6 can now be classified as a further inhibitory immune checkpoint on T cells," explains study leader Platten.

Some widespread cancer therapies with drugs from the checkpoint inhibitor (ICI) group are targeting certain inhibitory checkpoint molecules. They activate the immune system against the tumor by releasing the immune brakes. Could the B7H6-mediated elimination of tumor-reactive T cells possibly counteract the effect of ICI cancer immunotherapy? The researchers tested this using tissue samples from patients with esophageal cancer who had received ICI therapy. Those patients who had not responded to ICI had a higher number of NK cells in the tumor tissue and actually had a shorter progression-free survival time.

Cellular immunotherapy more effective in the absence of NK cells

Cellular immunotherapies are becoming increasingly important in cancer medicine. For example, some forms of blood cancer are now often treated with so-called CAR-T cells, which are equipped with customized receptors against the cancer. However, the success of therapy is often limited as the number of therapeutic cells in the patient's body declines rapidly.

The therapeutic CAR-T cells also carry B7H6 on the cell surface. Could NK cells be responsible for the rapid decline in their numbers after the start of therapy? Experiments with a humanized mouse model suggest this: if NK cells were added during CAR-T cell treatment of leukaemia, the number of therapeutic cells decreased, while the tumour load increased.

"NK control of T cells has the potential to interfere with various forms of cancer immunotherapy. By specifically intervening in this process, it may be possible to modulate T cell immune responses in the future," explains Michael Platten, head of the current study. With the help of the CRISPR-Cas gene scissors, the researchers now want to protect CAR-T cells from elimination by NK cells in a clinical trial together with the Department of Haematology and Oncology at Heidelberg University Hospital and thus improve the effectiveness of cellular immunotherapy.

 

Publication: M. Kilian et al.: The immunoglobulin superfamiliy ligand B7H6 subjects T cell responses to NK cell surveillance. Science Immunology 2024, DOI: 10.1126/sciimmunol.adj7970

 

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

 

National Center for Tumor Diseases (NCT, 6 sites)

German Cancer Consortium (DKTK, 8 sites)

Hopp Children's Cancer Center (KiTZ) Heidelberg

Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ

DKFZ-Hector Cancer Institute at the University Medical Center Mannheim

National Cancer Prevention Center (jointly with German Cancer Aid)

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

END


ELSE PRESS RELEASES FROM THIS DATE:

Wistar scientists discover new immunosuppressive mechanism in brain cancer

Wistar scientists discover new immunosuppressive mechanism in brain cancer
2024-05-03
PHILADELPHIA — (May 3, 2024) — The Wistar Institute assistant professor Filippo Veglia, Ph.D., and team, have discovered a key mechanism of how glioblastoma — a serious and often fatal brain cancer — suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses. The lab’s discovery was published in the paper, “Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma,” in the journal Immunity. “Our study shows that the cellular mechanisms of cancer’s self-preservation, when sufficiently understood, can be used against the disease very effectively,” ...

ADA Forsyth ranks number 1 on the East Coast in oral health research

ADA Forsyth ranks number 1 on the East Coast in oral health research
2024-05-03
Cambridge, Mass., – ADA Forsyth Institute (AFI) researchers received just under $10 million funding from the National Institute of Dental and Craniofacial Research (NIDCR) during the federal fiscal year 2023, placing 4th nationally on NIDCR’s ranking list. “We have ranked in the top 5 dental institutions in 9 out of the past 10 years,” said Wenyuan Shi, PhD, Chief Executive Officer of AFI. “We have placed in the top 10 nationally every year since the ranking system began in 2002, despite having one of the smallest faculty ...

The American Ornithological Society (AOS) names Judit Szabo as new Ornithological Applications editor-in-chief

The American Ornithological Society (AOS) names Judit Szabo as new Ornithological Applications editor-in-chief
2024-05-03
May 3, 2024—CHICAGO—The American Ornithological Society (AOS) is pleased to announce Judit K. Szabo, Ph.D., as the incoming editor-in-chief for its top-ranked journal, Ornithological Applications. Beginning on May 1, 2024, Szabo will work in partnership with the journal’s current editor-in-chief, Catherine Lindell, Ph.D., until June 30, 2024, and will take on full responsibility as editor-in-chief beginning on July 1, 2024. “With her international interest and network, conservation experience, and thoughtful approach ...

Catheter-directed mechanical thrombectomy system demonstrates safety and effectiveness in patients with pulmonary embolism

Catheter-directed mechanical thrombectomy system demonstrates  safety and effectiveness in patients with pulmonary embolism
2024-05-03
Long Beach, Calif. – May 3, 2024 – New data from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AX) demonstrated that catheter-directed mechanical thrombectomy is safe and effective in patients with acute intermediate-risk pulmonary embolism (PE) with significant improvement in the right ventricle (RV) function and minimal major adverse events. The safety and efficacy results from the prospective trial were presented today as late-breaking science at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.   Pulmonary embolism (PE), a blood clot that blocks and stops ...

Novel thrombectomy system demonstrates positive safety and feasibility results in treating acute pulmonary embolism

Novel thrombectomy system demonstrates positive safety and feasibility results in treating acute pulmonary embolism
2024-05-03
Long Beach, Calif. – May 3, 2024 – Late-breaking data from the ENGULF trial showed that a novel dual-action thrombectomy device was effective and safe in treating acute pulmonary embolism (PE). The safety and effectiveness results were presented today as late-breaking science at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and simultaneously published in JSCAI.   PE is a serious cardiovascular event where a blood clot causes issues with blood flow and oxygen levels in the lungs. It can be ...

Biomimetic transcatheter aortic heart valve offers new option for aortic stenosis patients

Biomimetic transcatheter aortic heart valve offers new option for aortic stenosis patients
2024-05-03
Long Beach, Calif. – May 3, 2024 – Recent findings from a study on a transcatheter heart valve (THV) system, which includes a new class of transcatheter aortic valve, showed positive results in the device's ability to function as a healthy and natural aortic valve in patients with aortic stenosis (AS). The late-breaking data will be presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.   AS is a thickening and narrowing of the aortic valve that can reduce blood flow to ...

SMART trial reaffirms hemodynamic superiority of TAVR self-expanding valve in aortic stenosis patients with a small annulus over time and regardless of age

SMART trial reaffirms hemodynamic superiority of TAVR self-expanding valve in aortic stenosis patients with a small annulus over time and regardless of age
2024-05-03
Long Beach, Calif. – May 3, 2024 – Additional analysis from the SMall Annuli Randomized To Evolut or SAPIEN (SMART) study demonstrated clinical non-inferiority of self-expanding valves (SEV) versus balloon-expandable valves (BEV) in aortic stenosis patients undergoing transcatheter aortic valve replacement (TAVR) and confirmed valve performance superiority over time based on hemodynamics. Data also showed similar positive results in two age groups (< or ≥ 80 years old). The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions ...

Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition

Metastatic prostate cancer research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition
2024-05-03
Study Title: Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore) Publication: American Urological Association Annual Meeting Plenary, May 3, 2024 Dana-Farber Cancer Institute author: Xiao X. Wei, MD Summary: In a follow-on analysis of results from the phase 3 PSMAfore study, clinical investigators from Dana-Farber and elsewhere found that clinical outcomes consistently favored 177Lu-PSMA-617 over a change from one androgen receptor pathway inhibitor (ARPI) to another, regardless of which ARPI patients received first. ...

Studies highlight need for tailored treatment options for women with peripheral artery disease

Studies highlight need for tailored treatment options for women with peripheral artery disease
2024-05-03
Late-Breaking Data Shows Endovascular Therapy Results in One-Third Reduction in Post-Procedural Complications for Women with PAD   Women and Asian Americans Less Likely to Undergo Endovascular Revascularization for PAD Compared to Men and Other Races    Long Beach, Calif. – May 3, 2024 – New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral artery disease (PAD), including endovascular therapy and revascularization. The data ...

Women and Black patients less likely to receive catheter-based treatment for pulmonary embolism

Women and Black patients less likely to receive catheter-based treatment for pulmonary embolism
2024-05-03
Long Beach, Calif. – May 3, 2024 – New data from the REAL-PE analysis investigated catheter-based pulmonary embolism (PE) treatment, showing women and Black people were less frequently treated with minimally invasive therapy compared to men or non-Black patients. The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.                                                                                                              ...

LAST 30 PRESS RELEASES:

From camera to lab: Dr. Etienne Sibille transforms brain aging and depression research

Depression rates in LGBTQIA+ students are three times higher than their peers, new research suggests

Most parents don’t ask about firearms in the homes their kids visit

Beer-only drinkers’ diets are worse than wine drinkers

Eco-friendly biomass pretreatment method yields efficient biofuels and adsorbents

How graph convolutions amplify popularity bias for recommendation?

New lignin-based hydrogel breakthrough for wound healing and controlled drug release

Enhancing compatibility and biodegradability of PLA/biomass composites via forest residue torrefaction

Time alone heightens ‘threat alert’ in teenagers – even when connecting on social media

Study challenges long-held theories on how migratory birds navigate 

Unlocking the secrets of ketosis

AI analysis of PET/CT images can predict side effects of immunotherapy in lung cancer

Making an impact. Research studies a new side of helmet safety: faceguard failures

Specific long term condition combinations have major role in NHS ‘winter pressures’

Men often struggle with transition to fatherhood amid lack of targeted information and support

More green space linked to fewer preventable deaths in most deprived areas of UK

Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma

A formula for life? New model calculates chances of intelligent beings in our Universe and beyond

Could a genetic flaw be the key to stopping people craving sugary treats?

Experts urge complex systems approach to assess A.I. risks

Fossil fuel CO2 emissions increase again in 2024

Winners of Applied Microbiology International Horizon Awards 2024 announced

A toolkit for unraveling the links between intimate partner violence, trauma and substance misuse

Can everyday physical activity improve cognitive health in middle age?

Updated guidance reaffirms CPR with breaths essential for cardiac arrest following drowning

Study reveals medical boards rarely discipline physician misinformation

New treatment helps children with rare spinal condition regain ability to walk

'Grow Your Own' teacher prep pipeline at the University of Louisiana at Lafayette funded by US Department of Education

Lab-grown human immune system uncovers weakened response in cancer patients

More than 5 million Americans would be eligible for psychedelic therapy, study finds

[Press-News.org] Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies